Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

Inhibiting effects of Metformin on Ovarian Hyperstimulation Syndrome (OHSS) in induction of ovulation with gonadotropin in ART cycles on women with Polycystic Ovary Syndrome (PCOS)

Authors
Marzieh Agha Hossinei
Ashraf Alyasin
Mojgan Khalili
Department of Obstet . and Gynecol ,Shariati Hospital, Tehran Medical Sciences University, Tehran, Iran
Abstract
In this research, it is supposed that treatment with Metformin prior to ovulation induction with gonadotropins in ART cycles, would be able to prevent OHSS and its severity among women with PCOS. This study was a randomized clinical trial on 100 women with PCOS who were treated in ART cycles. These women were divided randomly in two groups A and B ( 50 subjects each ). Group A received 500 mg of Metformin daily for about one month before induction ovulation with HMG and continued this treatment for about 45 days . Induction of ovulation protocol (classic long protocol) were similar in both groups. At the end of study the following results were compared in both groups : The serum Estradiol (E2) level on day of HCG administration and HMG doses (daily and total) were significantly lower in group A (P<0.002 and P<0.001 respectively). The number of women with OHSS and its severity and the number of admission in group A were lower than group B (P<0.001 and P<0.02, respectively), but the numbers of oocyte, pregnancy and the duration of treatment with HMG were similar in both groups. These results show that Metformin by reducing resistance to insulin and hyperandrogenism, leads to reduction in E2 level and favors orderly follicular growth in response to exogenous gonadotropin and it reduces the risk and severity of OHSS.
Keywords
Assisted Reproductive Techniques
Induction ovulation
Metformin
Ovarian hyperstimulation syndrome
Polycystic ovary syndrome
Speroff L., Glass R.H., Kase N.G. Text book of clinical Gynecologic Endocrinology and Infertility, 6th Edition. Lippincott williams & wilkins. 1999; (12): 487-521, (30):1097-133.
Adashi E.Y., Rak J.A., Rosenworks Z. Text book of reproductive endocrinology surgery and technology. Lippincott –Raven Publishers. Philadelphia. 1996; 2(117): 2216-30.
Whelan J.G., Vlahos N.F. The ovarian hyperstimulation syndrome. Fertil Steril. 2000; 73 (5): 884-95.
Nestler J.E., Jakubowizz D.J., Evans W.S. Effects of Metformin on spontaneous and Clomiphen induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998; 338(26): 1876-80.
Leo V., Lamarca A. Effect of Metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 1999; 72 (2): 282-5.
Golan A. The ovarian hyperstimulation syndrome. Fertil Steril. 1989; 44:430-40.
Nestler J.E., Jakubowicz D.J. Activity and serum androgens. J Clin Endocrinol Metab. 1997; 82(12): 4075-9.
Stadtmauer L.A., Toma S.K. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril. 2001;75(3): 505-9.
Morin Papunen L.C., Koivunen R.M. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effect in women with polycystic ovary syndrome. Fertil Steril. 1998; 69(4):691-6.
Velazquez E., Acosta A. Menstrual cyclicity after Metformin therapy in polycystic ovary syndrome. Obs Gyn. 1997; 90(3): 392-5.
Fulghesu A.M., Villa P. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab. 1997; 82(2): 644-8.
Goodman Gilman A., Rall T.W., Nies S., et al. The pharmacological basis of therapeutics, 9th Edition. Maxwell Macmillan International Editions. 1996; 2 (61): 1487-96.
Journal of Reproduction & Infertility
Volume 2, Issue 2
Spring 2001
Pages 42-47